Markets:

Overview

News

Currencies

International

Treasuries

Cogent Biosciences, Inc. - Common Stock (NQ:COGT)

34.51 +0.57 (+1.68%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cogent Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗

May 23, 2026

This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗

May 23, 2026

Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.

Via The Motley Fool

What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing ↗

May 18, 2026

Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.

Via The Motley Fool

Cogent Biosciences Inc (NASDAQ:COGT) Shows Bullish Technical Breakout Setup with High Scores ↗

May 02, 2026

Via Chartmill

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish ↗

May 18, 2026

Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.

Via The Motley Fool

Topics Regulatory Compliance

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗

May 17, 2026

Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases.

Via The Motley Fool

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗

May 17, 2026

Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗

May 17, 2026

Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease.

Via The Motley Fool

Topics Regulatory Compliance

This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗

May 17, 2026

This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and pulmonary targets.

Via The Motley Fool

Topics Regulatory Compliance

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗

May 16, 2026

This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials.

Via The Motley Fool

The Great Rotation of 2026: Why Small Caps are Finally Dethroning the Tech Giants

March 27, 2026

The financial landscape of 2026 has been defined by a seismic shift in capital allocation that few analysts predicted with such intensity. For the first time in over a decade, the long-dormant Russell...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

The Great Rotation: Small-Caps Seize Market Leadership in Historic 2026 Breakout

March 25, 2026

The financial landscape has undergone a tectonic shift in the opening months of 2026, as the long-dormant Russell 2000 index has surged to record highs, marking what many analysts believe is the...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗

March 21, 2026

Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.

Via The Motley Fool

Topics Regulatory Compliance

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗

March 21, 2026

This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗

March 21, 2026

This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗

March 21, 2026

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗

March 21, 2026

This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment.

Via The Motley Fool

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗

March 20, 2026

This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.

Via The Motley Fool

Topics Regulatory Compliance

This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain ↗

March 18, 2026

Axsome Therapeutics develops therapies for central nervous system disorders, with a late-stage pipeline targeting major unmet medical needs.

Via The Motley Fool

Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? ↗

March 18, 2026

This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators.

Via The Motley Fool

Topics Regulatory Compliance

This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names ↗

March 18, 2026

This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish ↗

March 18, 2026

This clinical-stage biotech develops therapies for CML, NASH, and obesity.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision ↗

March 13, 2026

Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.

Via The Motley Fool

Topics Regulatory Compliance

Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug ↗

March 13, 2026

Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.

Via The Motley Fool

Topics Regulatory Compliance

Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline ↗

March 13, 2026

Praxis Precision Medicines develops therapies for central nervous system disorders, targeting unmet needs in neurology and psychiatry.

Via The Motley Fool

Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗

March 13, 2026

This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.

Via The Motley Fool

Topics Regulatory Compliance

The Small-Cap Renaissance: Russell 2000 Eclipses Big Tech in Historic Early 2026 Surge

March 12, 2026

As the first quarter of 2026 passes its midway point, a seismic shift in market leadership is unfolding on Wall Street. After years of playing second fiddle to the "Magnificent Seven" and the...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗

February 17, 2026

This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.

Via The Motley Fool

Topics Regulatory Compliance

Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗

February 17, 2026

Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.

Via The Motley Fool

Topics Regulatory Compliance

Large Biotech Fund Sells Shares of Cogent Biosciences for Over $120M ↗

February 01, 2026

A large biotech fund that's an insider at Cogent Biosciences recently sold millions of shares amid the company's best annual performance ever in 2025.

Via The Motley Fool

Topics Regulatory Compliance

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.